Innate Pharma S.A. Sponsored ADR (IPHA)
Summary
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.
Innate Pharma S.A. Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Didric Cederholm Lion Point Capital LP | 81,151 | $142,014 | $118,480.46 | -$23,533.54 | -16.57% |
 Christopher C. Powers Farther Finance Advisors, LLC | 10 | $18.1 | $14.3 | -$3.8 | -20.99% |
Innate Pharma S.A. Sponsored ADR (IPHA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Innate Pharma S.A. Sponsored ADR ever had a stock split?
Innate Pharma S.A. Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Jonathan E. Dickinson CEO | NASDAQ (NGS) Exchange | 45781K204 CUSIP |
| FR Country | 163 Employees | - Last Dividend | - Last Split | 17 Oct 2019 IPO Date |
Overview
Innate Pharma S.A. is a pioneering biotechnology company based in Marseille, France, with a global reach, dedicated to the development of innovative immunotherapies for cancer patients. Established in 1999, the company has carved a niche for itself in the oncology sector by focusing on novel treatments that harness the body's immune system to fight cancer. Innate Pharma’s work involves extensive collaboration and licensing agreements with industry giants such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, as well as a co-development and license agreement with MedImmune Limited. Through its cutting-edge research and development, Innate Pharma S.A. is committed to improving outcomes for patients facing various forms of cancer.
Products and Services
Innate Pharma S.A. boasts a robust portfolio of products at various stages of clinical development, each targeting critical aspects of cancer immunotherapy:
- Lacutamab (IPH4102): A pioneering anti-KIR3DL2 antibody designed for patients with cutaneous T-cell and peripheral T-cell lymphoma. It is currently undergoing Phase II clinical trials and showing promise for the treatment of refractory Sézary syndrome.
- Monalizumab: This immune checkpoint inhibitor is at the forefront of a Phase III clinical trial targeting advanced solid tumors, including colorectal and lung cancer, as well as head and neck cancer. It exemplifies Innate Pharma’s commitment to broadening the horizons of cancer treatment.
- IPH5201: A blocking antibody targeting the CD39 immunosuppressive pathway, now in Phase II clinical trials. This product represents a novel approach to weakening cancer's defenses against the immune system.
- IPH5301: An anti-CD73 antibody aimed at disrupting the immunosuppressive adenosine pathway. By promoting antitumor immunity, this antibody is a key player in Innate Pharma's strategy to enhance cancer immunotherapy.
- IPH6401: A BCMA-targeting NK cell engager, indicative of Innate Pharma’s efforts to leverage natural killer (NK) cells in the fight against cancer.
- IPH6101: A NKp46-based NK cell engager that targets CD123 with a proprietary multi-specific antibody format. This product underscores the innovative nature of Innate Pharma’s research.
- IPH62: An B7-H3-targeting NK cell engager that represents another facet of Innate Pharma's strategy to harness the power of the immune system against cancer.
- IPH43 and IPH45: Both are in preclinical trials, with IPH43 being an anti-MICA/B ADC and IPH45 being an antibody-drug conjugate (ADC), demonstrating Innate Pharma’s ongoing commitment to expanding its cancer treatment arsenal.
- IPH67: An undisclosed, multi-specific ANKET currently in preclinical trials, highlighting the company's continuous innovation in developing new cancer therapies.
Contact Information
